HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Corvus Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Corvus Pharmaceuticals, Inc.

Jan-23
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M CRVS GlobeNewswire
Jan-21
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock CRVS GlobeNewswire
Jan-20
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants CRVS GlobeNewswire
Jan-20
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire
Jan-16
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire
Jan-05
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference CRVS GlobeNewswire
Dec-08
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial CRVS GlobeNewswire
Nov-04
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results CRVS GlobeNewswire
Nov-03
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition CRVS GlobeNewswire
Oct-31
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference CRVS GlobeNewswire
Oct-28
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 CRVS GlobeNewswire
Oct-17
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 CRVS GlobeNewswire
Oct-02
Corvus Pharmaceuticals Appoints David Moore to Board of Directors CRVS GlobeNewswire
Aug-07
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results CRVS GlobeNewswire
Jul-31
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 CRVS GlobeNewswire
Jun-25
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis CRVS GlobeNewswire
Jun-11
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress CRVS GlobeNewswire
Jun-04
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire
May-28
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference CRVS GlobeNewswire
May-08
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results CRVS GlobeNewswire
May-08
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.